Recruiting
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma - CA018-005
Updated: 15 June, 2020 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Advanced Renal Cell Carcinoma - Must have at least 1 lesion with measurable disease - Life expectancy of at least 3 months - Karnofsky Performance Status (KPS) must be =>70% Exclusion Criteria: - Patients/subjects with suspected or known central nervous system metastases unless adequately treated - Patients/subjects with autoimmune disease - Patients/subjects who need daily oxygen therapy Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information